Additional Information Index Accounting policies 144, 199 Information Technology 22, 61, 220 Acerta Pharma 4, 56-57, 193 Infrastructure 61 Acquisitions 173-177 Intangible assets 71, 79-80, 101, 136, 145, 158-160, 239 Affordable Care Act 14, 49, 231 Intellectual Property 60 Almirall 68-73, 160, 174-176, 237-239 Interest-bearing loans and borrowings 163-164 Animal research 45 Key performance indicators 18-20 Annual General Meeting 82, 97, 245 Leases 146, 148, 192 Articles of Association 245 Life-cycle of a medicine 10-11 AstraZeneca at a glance 2 Litigation 22, 80-81, 101, 137, 147, 186-191, 199, 214-215, 218, 223 Audit Committee 84, 86-87, 98-102 Lynparza 34-38 Audit Committee Report 98-102 Manufacturing and Supply 46 Bioethics 44-45, 234 Market definitions 247 Biologics 10, 13 Marketplace 12-15 BMS 70-73, 174 Oncology 34-38 Board of Directors 86-87 Operating profit 1, 62-67, 150-151, 236 Brilinta Brilique 30-33 Operational overview 2 Business model 8-9 Other investments 147, 161 Cambridge 7, 42, 53-54 PARTHENON programme 33 Capitalisation and shareholder return 76 Patent Expiries 15 Cardiovascular and Metabolic diseases 30-33 Patents see Intellectual Property Cash and cash equivalents 69, 146, 163 Patient safety 22, 44-45 Chairmans Statement 82 Personalised healthcare 43-44 Chief Executive Officers Review 4 Physician Payments Sunshine Act 50 Clinical trials 45 Pipeline and Therapy Area Introduction 24-41 Code of Conduct 95-98 Political donations 97 Commitments and contingent liabilities 186-192 Post-retirement benefits 80, 101, 137, 166-171 Community investment 58-59 Primary care 10 Company history 245 Product revenue information 227-233 Compliance and Internal Audit Services 95 Property, plant and equipment 71, 146, 156, 238 Consolidated Statements 140-143 Provisions 165 Corporate Information 245 Regulatory requirements 13-14 Corporate Integrity Agreement 50 Related party transactions 193, 242 Corporate Governance 82-135 Relations with shareholders 93 Definiens 72, 175-176 Remuneration 107-116 Development pipeline 25, 205-209 Remuneration Policy 117-134 Diabetes 30-33 Research and Development 42-45 Directors interest in shares 114-115 Reserves 172 Directors responsibility statement 135 Respiratory, Inflammation and Autoimmunity 26-29 Diversity 52-53, 90-91 Restructuring 68, 150 Dividends 76, 96, 172 Results of operations 2014 238 Earnings per Ordinary Share 153 Results of operations 2015 65 Employee costs and share plans for employees 182-185 Risk 21, 212-226 Employees 52-54 Sales and Marketing 48-50 Ethics 50, 96 Sales by geographical area 227-233 Environmental impact 58 Sales by therapy area 24-41, 227-233 Finance income and expense 151 Sarbanes-Oxley Act 81 Financial instruments 146, 151, 161-162 Science Committee 85, 94 Financial position 2014 238-239 Segment information 154-155 Financial position 2015 71 Senior management SET 88-89 Financial Review 62-81 Share capital 172 Financial risk management 76-77, 177-182 Share repurchase 75, 172 Financial Statements 2015 135-202 Shareholder distributions 76, 96 Financial summary 2 Shareholder information 240-244 Financials 2014 236-239 Specialty care 10 Gender diversity 52-53 Strategic priorities 16-17 Geographical Review 227-233 Sustainability: supplementary information 234-235 Global pharmaceutical sales 12-13 Tagrisso 4, 34, 36 Glossary 247-249 Takeda 5, 28 Group Financial Record 202 Taxation 68, 76, 81, 146, 151-153, 199 Group Subsidiaries and Holdings 194-195 Taxation information for shareholders 242-244 Growth Platforms 7, 16-17 Trade and other payables 71, 146, 164-165, 239 Healthy Heart Africa programme 51 Trade and other receivables 71, 146, 163, 181 Human Rights 54 Trade marks 246 Independent auditors report 136-139 Values and purpose 8-9 Infection, Neuroscience and Gastrointestinal 39-41 Young Health Programme 59 Inflammation see Respiratory, Inflammation and Autoimmunity ZS Pharma 4, 72, 173 250 AstraZeneca Annual Report and Form 20-F Information 2015 Additional Information Important information for readers of this Annual Report Cautionary statement regarding Inclusion of Reported performance, AstraZeneca websites forward-looking statements Core financial measures and constant Information on or accessible through our The purpose of this Annual Report is to exchange rate growth rates websites, including www.
com, provide information to the members of the AstraZenecas determination of non-GAAP www.
The Company and its Directors, measures together with our presentation of www.
com, does not form employees, agents and advisers do not them within our financial information may part of and is not incorporated into this accept or assume responsibility to any other differ from similarly titled non-GAAP Annual Report.
person to whom this Annual Report is measures of other companies.
shown or into whose hands it may come External third party websites and any such responsibility or liability is Statements of competitive position, Information on or accessible through any expressly disclaimed.
In order, among other growth rates and sales third party or external website does not form things, to utilise the safe harbour provisions In this Annual Report, except as otherwise part of and is not incorporated into this of the US Private Securities Litigation stated, market information regarding the Annual Report.
Reform Act of 1995 and the UK Companies position of our business or products relative Act 2006, we are providing the following to its or their competition is based upon Figures cautionary statement: This Annual Report published statistical sales data for the Figures in parentheses in tables and in the contains certain forward-looking statements 12 months ended 30 September 2015 Financial Statements are used to represent with respect to the operations, performance obtained from IMS Health, a leading supplier negative numbers.
and financial condition of the Group, of statistical data to the pharmaceutical including, among other things, statements industry.
Unless otherwise noted, for the about expected revenues, margins, US, dispensed new or total prescription earnings per share or other financial or other data and audited sales data are taken, measures.
Forward-looking statements are respectively, from IMS Health National statements relating to the future which are Prescription Audit and IMS National Sales based on information available at the time Perspectives for the 12 months ended such statements are made, including 31December 2015: such data is not information relating to risks and adjusted for Medicaid and similar rebates.
Although we believe that the Except as otherwise stated, these market forward-looking statements in this Annual share and industry data from IMS Health Report are based on reasonable have been derived by comparing our sales assumptions, the matters discussed in the revenue with competitors and total market forward-looking statements may be sales revenues for that period.
Except as influenced by factors that could cause otherwise stated, growth rates are given actual outcomes and results to be materially at CER.
For the purposes of this Annual different from those expressed or implied Report, unless otherwise stated, references by these statements.
The forward-looking to the world pharmaceutical market or statements reflect knowledge and similar phrases are to the 54 countries information available at the date of the contained in the IMS Health database, preparation of this Annual Report and the which amounted to approximately 97% Company undertakes no obligation to in value of the countries audited by update these forward-looking statements.
We identify the forward-looking statements by using the words anticipates, believes, expects, intends and similar expressions in such statements.
Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those factors identified in the Risk section from page 212 of this Annual Report.
Nothing in this Annual Report should be construed as a profit forecast.
AstraZeneca Annual Report and Form 20-F Information 2015 251 Additional Information Registered office and corporate Registrar headquarters Equiniti Limited AstraZeneca PLC Aspect House 2 Kingdom Street Spencer Road London W2 6BD Lancing UK West Sussex BN99 6DA Tel: 44 0 20 7604 8000 UK Tel: freephone in the UK 0800 389 1580 Investor relations Tel: outside the UK 44 0 121 415 7033 UK: as above Swedish Central Securities Depository US: Euroclear Sweden AB Investor Relations PO Box 191 AstraZeneca Pharmaceuticals LP SE-101 23 Stockholm One MedImmune Way Sweden Gaithersburg MD 20878 Tel: 46 0 8 402 9000 US Tel: 1 301 398 0000 US Depositary Citibank Shareholder Services PO Box 43077 Providence RI 02940-3077 US Tel: toll free in the US 1 888 697 8018 For more information please see Tel: outside the US 1 781 575 4555 www.
com 252 AstraZeneca Annual Report and Form 20-F Information 2015 This Annual Report is printed on Heaven 42 which is FSC Designed and produced by certified virgin fibre.
The pulp is a mix: partly bleached using an Elemental Chlorine Free ECF process and partly bleached using a Totally Chlorine Free process.
It is printed in the UK Board and SET photography by Pureprint using its and environmental by Marcus Lyon printing technology, and vegetable inks were used throughout.
Both the manufacturing mill and the printer are registered to the Environmental Management System ISO 14001 and are Forest Stewardship Council chain-of-custody certified.
AstraZeneca Annual Report and Form 20-F Information 2015 AstraZeneca PLC 2 Kingdom Street London W2 6BD UK T: 44 0 20 7604 8000 This Annual Report is also available on our website, www.
